Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Mon, Jun 29, 2026

1 updates

7:25 AM

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Trial Start • Phase 2Trial initiation Mon, Jun 29, 2026, 7:25 AM EDTtonixpharma.com

Thu, Jun 11, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

tonixpharma.com

Mon, Jun 8, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

tonixpharma.com

Thu, May 28, 2026

1 updates

4:30 PM

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

tonixpharma.com

Wed, May 27, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

tonixpharma.com

Tue, May 26, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

tonixpharma.com

Thu, May 14, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026

tonixpharma.com

Tue, May 12, 2026

1 updates

4:30 PM

Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

tonixpharma.com

Mon, May 11, 2026

1 updates

4:30 PM

Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights

tonixpharma.com

Wed, May 6, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

tonixpharma.com

Wed, Apr 29, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University

Presentation / Abstract • Phase 1tonixpharma.com

Thu, Apr 23, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

tonixpharma.com

Wed, Apr 15, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

tonixpharma.com